← Back to headlines
Novartis Gene Therapy Itvisma Approved in EU
Novartis's gene therapy, Itvisma, has received approval for use in the European Union to treat spinal muscular atrophy, marking a significant development for patients with the condition.
2 Jul, 18:20 — 2 Jul, 18:20
Sources
Showing 1 of 1 sources
